Tags : Hereditary Cancer Syndrome


Recursion Signs a Worldwide License Agreement with Takeda to Develop

Shots: Recursion to get exclusive WW rights to develop and commercialize TAK-733 for the treatment of a hereditary cancer syndrome and related areas of oncology Recursion will utilize its automated drug discovery platform to discover the potential of TAK-733 by testing 200+ potential molecules from Takeda’s library against cancers carrying mutations TAK-733 is identified as […]Read More